Latest BIAFW ETF News Today | Earnings, Events & Price Alerts

BIAFW News

bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume

Nov 05 2025Newsfilter

bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations

Oct 09 2025Newsfilter

bioAffinity Technologies, Inc. Reveals About $1.8 Million Registered Direct Offering of Common Stock Priced According to Nasdaq Regulations

Oct 08 2025Newsfilter

bioAffinity Technologies Completes $4.8 Million Public Offering

Sep 30 2025Newsfilter

bioAffinity Technologies Expands Collection of Case Studies Highlighting Clinical Benefits of CyPath® Lung

Sep 26 2025Newsfilter

bioAffinity Technologies Adds New Directors to Its Board

Aug 18 2025Newsfilter

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14 2025Newsfilter

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13 2025Newsfilter

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26 2025Newsfilter

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11 2025Newsfilter

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28 2025Newsfilter

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20 2025Newsfilter

bioAffinity Technologies Reports First Quarter 2025 Results

May 15 2025Newsfilter

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 07 2025Newsfilter

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17 2025Newsfilter

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26 2025Newsfilter

BIAFW

BIAFW

BIAFW News

bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume

bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations

bioAffinity Technologies, Inc. Reveals About $1.8 Million Registered Direct Offering of Common Stock Priced According to Nasdaq Regulations

bioAffinity Technologies Completes $4.8 Million Public Offering

bioAffinity Technologies Expands Collection of Case Studies Highlighting Clinical Benefits of CyPath® Lung

bioAffinity Technologies Adds New Directors to Its Board

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas&#39; Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

bioAffinity Technologies Announces Closing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Case Study: bioAffinity Technologies&#39; CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer